2-(4-Ethyl-phenylamino)-N-(4-sulfamoyl-benzyl)-acetamide

ID: ALA4869520

PubChem CID: 164621917

Max Phase: Preclinical

Molecular Formula: C17H21N3O3S

Molecular Weight: 347.44

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  CCc1ccc(NCC(=O)NCc2ccc(S(N)(=O)=O)cc2)cc1

Standard InChI:  InChI=1S/C17H21N3O3S/c1-2-13-3-7-15(8-4-13)19-12-17(21)20-11-14-5-9-16(10-6-14)24(18,22)23/h3-10,19H,2,11-12H2,1H3,(H,20,21)(H2,18,22,23)

Standard InChI Key:  MWCROTDHJPPFED-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 24 25  0  0  0  0  0  0  0  0999 V2000
   14.8250  -21.6052    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.5320  -21.1953    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   16.2453  -21.6053    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.9556  -21.1899    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.2484  -22.4266    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   17.6690  -21.6000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   18.3752  -21.1846    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.0845  -21.5964    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.7944  -21.1817    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.7917  -20.3595    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.0734  -19.9538    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.3665  -20.3667    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.1166  -21.1980    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.5982  -20.5437    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   12.0438  -19.8565    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
   11.2279  -19.8148    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   13.4653  -19.9339    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.7316  -20.3083    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.6922  -21.1286    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.3819  -21.5773    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.1561  -20.3770    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.0856  -19.0442    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   20.4968  -19.9464    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.2071  -20.3506    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  3  1  0
  3  4  1  0
  3  5  2  0
  4  6  1  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12  7  1  0
  2  1  1  0
  1 13  1  0
 15 14  2  0
 16 15  2  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 20 13  1  0
 13 21  2  0
 21 17  1  0
 18 15  1  0
 15 22  1  0
 10 23  1  0
 23 24  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4869520

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 347.44

Molecular Weight (Monoisotopic): 347.1304

AlogP: 1.62

#Rotatable Bonds: 7

Polar Surface Area: 101.29

Molecular Species: NEUTRAL

HBA: 4

HBD: 3

#RO5 Violations: ┄

HBA (Lipinski): 6

HBD (Lipinski): 4

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 10.22

CX Basic pKa: 2.91

CX LogP: 1.63

CX LogD: 1.63

Aromatic Rings: 2

Heavy Atoms: 24

QED Weighted: 0.71

Np Likeness Score: -1.76

References

1. Mishra CB, Kumari S, Angeli A, Bua S, Mongre RK, Tiwari M, Supuran CT..  (2021)  Discovery of Potent Carbonic Anhydrase Inhibitors as Effective Anticonvulsant Agents: Drug Design, Synthesis, and In Vitro and In Vivo Investigations.,  64  (6.0): [PMID:33721499] [10.1021/acs.jmedchem.0c01889]

Source

Source(1):

• Scientific Literature